Rep. April McClain Delaney Sells Bio-Techne Corp (NASDAQ:TECH) Stock
by Mitch Edgeman · The Markets DailyRepresentative April McClain Delaney (Democratic-Maryland) recently sold shares of Bio-Techne Corp (NASDAQ:TECH). In a filing disclosed on April 06th, the Representative disclosed that they had sold between $1,001 and $15,000 in Bio-Techne stock on March 26th.
Representative April McClain Delaney also recently made the following trade(s):
- Purchased $1,001 – $15,000 in shares of Entegris (NASDAQ:ENTG) on 3/31/2026.
- Purchased $1,001 – $15,000 in shares of Somnigroup International (NYSE:SGI) on 3/31/2026.
- Purchased $1,001 – $15,000 in shares of Rollins (NYSE:ROL) on 3/31/2026.
- Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 3/31/2026.
- Purchased $1,001 – $15,000 in shares of Nasdaq (NASDAQ:NDAQ) on 3/31/2026.
- Purchased $1,001 – $15,000 in shares of Packaging Corporation of America (NYSE:PKG) on 3/20/2026.
- Purchased $1,001 – $15,000 in shares of Nasdaq (NASDAQ:NDAQ) on 3/18/2026.
- Purchased $1,001 – $15,000 in shares of Packaging Corporation of America (NYSE:PKG) on 3/17/2026.
- Purchased $1,001 – $15,000 in shares of Somnigroup International (NYSE:SGI) on 3/16/2026.
- Purchased $1,001 – $15,000 in shares of Tractor Supply (NASDAQ:TSCO) on 3/16/2026.
Bio-Techne Price Performance
Bio-Techne stock traded up $0.36 during trading on Thursday, reaching $55.57. The company had a trading volume of 2,239,626 shares, compared to its average volume of 2,411,060. The firm’s 50-day simple moving average is $56.64 and its 200 day simple moving average is $59.76. Bio-Techne Corp has a 1-year low of $46.01 and a 1-year high of $72.16. The firm has a market capitalization of $8.69 billion, a PE ratio of 108.96, a price-to-earnings-growth ratio of 3.49 and a beta of 1.49. The company has a debt-to-equity ratio of 0.13, a quick ratio of 3.08 and a current ratio of 4.54.
Bio-Techne (NASDAQ:TECH – Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.43 by $0.03. The business had revenue of $295.88 million for the quarter, compared to the consensus estimate of $290.20 million. Bio-Techne had a net margin of 6.67% and a return on equity of 13.94%. The company’s revenue was down .4% compared to the same quarter last year. During the same period last year, the firm posted $0.42 earnings per share. As a group, equities research analysts anticipate that Bio-Techne Corp will post 1.67 earnings per share for the current fiscal year.
Bio-Techne Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, February 27th. Investors of record on Monday, February 16th were paid a $0.08 dividend. The ex-dividend date of this dividend was Friday, February 13th. This represents a $0.32 dividend on an annualized basis and a yield of 0.6%. Bio-Techne’s dividend payout ratio (DPR) is currently 62.75%.
Hedge Funds Weigh In On Bio-Techne
Hedge funds and other institutional investors have recently modified their holdings of the business. Blue Trust Inc. lifted its stake in shares of Bio-Techne by 109.7% in the third quarter. Blue Trust Inc. now owns 453 shares of the biotechnology company’s stock worth $25,000 after buying an additional 237 shares in the last quarter. Danske Bank A S purchased a new position in shares of Bio-Techne in the fourth quarter worth about $29,000. eCIO Inc. purchased a new position in shares of Bio-Techne in the fourth quarter worth about $30,000. Measured Wealth Private Client Group LLC purchased a new position in shares of Bio-Techne in the third quarter worth about $32,000. Finally, iSAM Funds UK Ltd purchased a new position in shares of Bio-Techne in the third quarter worth about $33,000. 98.95% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analysts Forecast Growth
Several equities analysts have issued reports on TECH shares. Benchmark reaffirmed a “buy” rating on shares of Bio-Techne in a report on Tuesday, February 3rd. Citigroup reaffirmed a “buy” rating and set a $80.00 price objective (up from $70.00) on shares of Bio-Techne in a report on Wednesday, February 4th. UBS Group reaffirmed a “buy” rating and set a $79.00 price objective (up from $70.00) on shares of Bio-Techne in a report on Thursday, February 5th. Stifel Nicolaus set a $65.00 price objective on shares of Bio-Techne and gave the company a “hold” rating in a report on Thursday, February 5th. Finally, Evercore increased their price objective on shares of Bio-Techne from $62.00 to $68.00 and gave the company an “in-line” rating in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Bio-Techne currently has an average rating of “Moderate Buy” and a consensus target price of $72.77.
Check Out Our Latest Research Report on TECH
About Representative McClain Delaney
April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.
McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.
April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.
Bio-Techne Company Profile
Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.
Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.